No Known Direct Interaction Risks
Vascepa (icosapent ethyl), a prescription omega-3 fatty acid used to lower triglycerides, has no documented pharmacokinetic or pharmacodynamic interactions with vitamin D supplements in clinical data or drug interaction checkers.[1][2] Major databases like Drugs.com and WebMD report no alerts for this combination, and Vascepa's prescribing information does not list vitamin D as a concern.[3]
Potential Indirect Effects on Heart Health
Both Vascepa and vitamin D support cardiovascular function—Vascepa reduces plaque buildup and heart events in high-risk patients, while vitamin D aids blood pressure regulation and inflammation control.[4] Over-supplementing vitamin D (above 4,000 IU daily) can raise calcium levels, potentially increasing risks like kidney stones or arrhythmias, which might compound Vascepa's rare side effects such as atrial fibrillation (1-2% incidence).[5][6] Standard doses (1,000-2,000 IU vitamin D) show no such overlap.
What Happens If You Take High Doses Together?
Excess vitamin D hypercalcemia could theoretically strain the liver or kidneys, where Vascepa is metabolized (via CYP3A pathways, minimally affected by vitamin D).[7] No case reports link the two, but patients on Vascepa with existing kidney issues should monitor vitamin D levels via blood tests to avoid compounding effects.[8]
Patient Experiences and Bleeding Concerns
Anecdotal reports on forums like Reddit note no issues, though Vascepa mildly thins blood (increasing bleeding risk with anticoagulants, not vitamin D).[9] Vitamin D at normal doses does not affect clotting. Those with low vitamin D starting Vascepa often correct deficiency safely under doctor guidance.
When to Check with a Doctor
Consult a physician before combining if you have kidney disease, take statins (common with Vascepa), or exceed 10,000 IU vitamin D daily—bloodwork for 25(OH)D and calcium ensures safety.[10] No patent or regulatory issues tie to this combo on DrugPatentWatch.com.[11]
Sources
[1] Drugs.com - Vascepa Interactions: https://www.drugs.com/drug-interactions/icosapent%2Cvascepa.html
[2] WebMD - Vascepa Details: https://www.webmd.com/drugs/2/drug-166384/vascepa-oral/details
[3] Vascepa Prescribing Information (FDA): https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/202057s019lbl.pdf
[4] REDUCE-IT Trial (NEJM): https://www.nejm.org/doi/full/10.1056/NEJMoa1812792
[5] NIH Vitamin D Fact Sheet: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
[6] Amarin REDUCE-IT Post-Hoc Analysis: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.050446
[7] Clinical Pharmacology Review (FDA): https://www.accessdata.fda.gov/drugsatfdadocs/nda/2012/202057Orig1s000ClinPharmR.pdf
[8] KDIGO Guidelines on CKD: https://kdigo.org/guidelines/ckd-evaluation-and-management/
[9] Patient Forums (aggregated, e.g., Drugs.com Reviews): https://www.drugs.com/comments/icosapent-ethyl/vascepa.html
[10] AHA Omega-3 Recommendations: https://www.heart.org/en/healthy-living/healthy-eating/eat-smart/fats/fish-and-omega-3-fatty-acids
[11] DrugPatentWatch - Vascepa: https://www.drugpatentwatch.com/p/tradename/VASCEPA